Lilly R&D personnel changes
Leader of Lilly's Zyprexa product team and clinical research fellow Alan Breier, MD, assumes Chief Medical Officer and VP-Medical position; Breier replaces Michael McDonald, MD, who is leaving Lilly. VP-Clinical Research and U.S. Regulatory Affairs and Policy Tim Franson, MD, replaces Michael Clayman, MD, as VP-Global Regulatory Affairs; Clayman moves into the new position of VP-Lilly Research Laboratories. Breier and Franson report to Steven Paul, MD, recently appointed R&D president (1"The Pink Sheet" May 19, 2003, p. 16)...
You may also be interested in...
Lilly R&D president-elect Steven Paul, MD, will bring an extensive background in central nervous system discovery and research to Lilly's top research position
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.